Accuray (ARAY) closed at $0.11 on November 6, 2026, down 11.3% from the previous close, on volume of 1,770,325 shares (30-day average 15,032,127).
Data as of November 6, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Upcoming Stock Splits This Week (November 9 to November 13) – Stay Invested
TipRanks (Sun, 8-Nov 1:36 PM ET)
Accuray Reports Fiscal 2027 First-Quarter Financial Results
TipRanks (Wed, 4-Nov 5:03 PM ET)
Accuray GAAP EPS of $0.07, revenue of $86.5M misses by $7.4M
Seeking Alpha News (Wed, 4-Nov 4:58 PM ET)
Accuray Announces 1-for-40 Reverse Stock Split
PRNewswire (Wed, 4-Nov 4:20 PM ET)
Accuray Reports Fiscal 2027 First Quarter Financial Results
PRNewswire (Wed, 4-Nov 4:05 PM ET)
Here are the major earnings after the close Wednesday
Seeking Alpha News (Wed, 4-Nov 10:00 AM ET)
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
PRNewswire (Fri, 30-Oct 4:10 PM ET)
Accuray to Report First Quarter Fiscal 2027 Financial Results on November 4, 2026
PRNewswire (Wed, 21-Oct 4:05 PM ET)
PRNewswire (Tue, 6-Oct 4:10 PM ET)
Market Chameleon (Mon, 28-Sep 5:55 AM ET)
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention. The company has one operating segment which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients.
Accuray trades on the NASDAQ stock market under the symbol ARAY.
As of November 9, 2026, ARAY stock price declined to $3.64 with 107,339 million shares trading.
ARAY has a beta of 2.68, meaning it tends to be more sensitive to market movements. ARAY has a correlation of 0.12 to the broad based SPY ETF.
ARAY has a market cap of $10.94 million. This is considered a Sub-Micro Cap stock.
Last quarter Accuray reported $87 million in Revenue and $.07 earnings per share. This fell short of revenue expectation by $-9 million and exceeded earnings estimates by $.14.
In the last 3 years, ARAY traded as high as $122.00 and as low as $3.58.
The top ETF exchange traded funds that ARAY belongs to (by Net Assets): VTI, VXF, FESM, MSSM, PRFZ.
ARAY has underperformed the market in the last year with a price return of -92.5% while the SPY ETF gained +13.4%. ARAY has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -67.8% and -30.1%, respectively, while the SPY returned -1.9% and -1.0%, respectively.
ARAY support price is $4.06 and resistance is $4.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARAY shares will trade within this expected range on the day.
